Moderna jumps as vaccine shows benefit in head and neck cancer in early study

Moderna jumps as vaccine shows benefit in head and neck cancer in early study

Source: 
Reuters
snippet: 

Moderna (MRNA.O) shares rose 8% to a three-month high on Tuesday after the company's individualized cancer vaccine developed with Merck (MRK.N) showed positive response in an early-stage trial in patients with a type of head and neck cancer.